Invasive, deadly fungus affecting bats found in Rocky Mountain National Park
DENVER (KDVR) — An invasive fungus has been detected in bats at Rocky Mountain National Park.
In a Thursday press release from the national park, tests done by the U.S. Geological Survey confirmed the fungus known as Pseudogymnoascus destructans, or Pd, has been detected in bats in the Holzwarth Historic Site on the west side of Rocky Mountain National Park.
According to the park, this is the first confirmed detection of the fungus in Grand County.
Pd is described as an invasive fungus that causes white-nose syndrome — a deadly and infectious disease that impacts bats.
'Any new detection of Pd is worrisome because bats are vital for healthy ecosystems. Rocky Mountain National Park is home to nine known species of bats, five of which have been found living in areas above 11,000 feet,' said Rocky Mountain National Park in a press release.
How much snow will fall in the high country this weekend?
While white-nose syndrome does not pose a risk to humans, people can spread the disease.
Following the detection, Rocky Mountain National Park has provided protection tips to visitors. The park asks people to report dead or injured bats to park personnel. The park also said people should never touch a bat, because they could carry other dangerous diseases aside from white-nose syndrome.
If you do visit a cave or bat habitat, Rocky Mountain National Park recommends you properly decontaminate gear and outerwear.
The national park said white-nose syndrome was first confirmed in 2022 in southeastern Colorado, it has also been confirmed in Larimer County.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Nika Pharmaceuticals, Inc. to Present at the Life Sciences Virtual Investor Forum June 11th-12th
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at HENDERSON, Nev., June 10, 2025 (GLOBE NEWSWIRE) -- Nika Pharmaceuticals, Inc. (OTCQB:NIKA), based in Colorado, focused on cures for life-threatening diseases, today announced that Dimitar Savov, CEO, will present live at the Life Sciences Virtual Investor Frum hosted by on June 11th, 2025 DATE: June 11th TIME: 1:00 PM ETLINK: REGISTER HEREAvailable for 1x1 meetings: June 12th-17th between 09:00am ET and 11:30am ET This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event. It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates. Learn more about the event at Recent Company Highlights On May 19, 2025, NIKA published a market analysis for the countries of Ukraine, Syria, Jordan, Iraq, UAE, where NIKA has exclusive distribution agreements and has estimated a total of around €656 million in potential revenue. NIKA's partner company, Nika Europe, has made the second $195,554 payment for the vial production line and is currently finalizing the details of the clean rooms design in order to start construction. The production facility is expected to be completed in H2, 2025. On April 11, 2025, Nika Pharmaceuticals, Inc. published a report on the therapeutic effect and potential economic impact of ITV-1, which can be found here. On July 11, 2024 Nika Pharmaceuticals, Inc. signed an exclusive distribution agreement for the Republic of Nigeria. Under the terms, NIKA will receive €1,980 per each set of ITV-1 with two sets necessary for each treatment, which could result in €7.9 billion revenue. About Nika Pharmaceuticals, Inc. Nika Pharmaceuticals, Inc. (NIKA) is a pharmaceutical company, specializing in the treatment of HIV/AIDS, Hepatitis B and C, Rheumatoid Arthritis, Cancer, Diabetes, and all diseases, for which strengthened cell immunity is of vital importance. NIKA's intellectual property includes six drugs in injection form – two of which have successfully undergone clinical trials with good treatment results – four drugs in tablet form, and eleven dietary supplements. NIKA's goal is to not only achieve corporate profits, but to provide better and easier access to life-saving medicinal drugs and useful dietary supplements. Find more on Forward-looking Statement: This press release contains forward-looking statements. Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are 'forward- looking statements.' These forward-looking statements generally are identified by the words 'believes,' 'expects,' 'anticipates,'' estimates,' 'intends,' 'strategy,' 'plan,' 'may,' 'will,' 'would,' 'will be,' 'will continue,' 'will likely result,' and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. About Virtual Investor Conferences®Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors. Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors. CONTACTS:Nika Pharmaceuticals, Clifford P. RedekopTitle Corporate SecretaryPhone (702) 326-3615 Email cliffredekop@ Virtual Investor Conferences John M. ViglottiSVP Corporate Services, Investor AccessOTC Markets Group (212) 220-2221johnv@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Nika Pharmaceuticals, Inc. to Present at the Life Sciences Virtual Investor Forum June 11th-12th
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at HENDERSON, Nev., June 10, 2025 (GLOBE NEWSWIRE) -- Nika Pharmaceuticals, Inc. (OTCQB:NIKA), based in Colorado, focused on cures for life-threatening diseases, today announced that Dimitar Savov, CEO, will present live at the Life Sciences Virtual Investor Frum hosted by on June 11th, 2025 DATE: June 11th TIME: 1:00 PM ETLINK: REGISTER HEREAvailable for 1x1 meetings: June 12th-17th between 09:00am ET and 11:30am ET This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event. It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates. Learn more about the event at Recent Company Highlights On May 19, 2025, NIKA published a market analysis for the countries of Ukraine, Syria, Jordan, Iraq, UAE, where NIKA has exclusive distribution agreements and has estimated a total of around €656 million in potential revenue. NIKA's partner company, Nika Europe, has made the second $195,554 payment for the vial production line and is currently finalizing the details of the clean rooms design in order to start construction. The production facility is expected to be completed in H2, 2025. On April 11, 2025, Nika Pharmaceuticals, Inc. published a report on the therapeutic effect and potential economic impact of ITV-1, which can be found here. On July 11, 2024 Nika Pharmaceuticals, Inc. signed an exclusive distribution agreement for the Republic of Nigeria. Under the terms, NIKA will receive €1,980 per each set of ITV-1 with two sets necessary for each treatment, which could result in €7.9 billion revenue. About Nika Pharmaceuticals, Inc. Nika Pharmaceuticals, Inc. (NIKA) is a pharmaceutical company, specializing in the treatment of HIV/AIDS, Hepatitis B and C, Rheumatoid Arthritis, Cancer, Diabetes, and all diseases, for which strengthened cell immunity is of vital importance. NIKA's intellectual property includes six drugs in injection form – two of which have successfully undergone clinical trials with good treatment results – four drugs in tablet form, and eleven dietary supplements. NIKA's goal is to not only achieve corporate profits, but to provide better and easier access to life-saving medicinal drugs and useful dietary supplements. Find more on Forward-looking Statement: This press release contains forward-looking statements. Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are 'forward- looking statements.' These forward-looking statements generally are identified by the words 'believes,' 'expects,' 'anticipates,'' estimates,' 'intends,' 'strategy,' 'plan,' 'may,' 'will,' 'would,' 'will be,' 'will continue,' 'will likely result,' and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. About Virtual Investor Conferences®Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors. Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors. CONTACTS:Nika Pharmaceuticals, Clifford P. RedekopTitle Corporate SecretaryPhone (702) 326-3615 Email cliffredekop@ Virtual Investor Conferences John M. ViglottiSVP Corporate Services, Investor AccessOTC Markets Group (212) 220-2221johnv@ nel recupero dei dati Effettua l'accesso per consultare il tuo portafoglio Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati
Business Wire
an hour ago
- Business Wire
Guided Therapeutics Receives $700,000 Purchase Order and Initial Payment from New Chinese Distributor
PEACHTREE CORNERS, Ga.--(BUSINESS WIRE)--Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of the LuViva Advanced Cervical Scan, announced today that it had received a purchase order and first payment from Hangzhou Dongye Medical Technology Company Ltd (HDMT) for 35 LuViva systems. HDMT will order directly from Guided Therapeutics and the devices will be assembled and tested by Guided Therapeutics' Chinese partner, Shandong Yaohua Medical Instrument Corporation (SMI). HDMT is in Hangzhou City, Zhejiang Province, where it is the exclusive gynecology products provider for 42 hospitals that perform approximately two million cervical cancer screenings annually. Said Yang Dongye, CEO of HDMT: 'We are extremely impressed with the performance of LuViva and our goal is to eventually replace the current screening tests with LuViva.' The purchase order for $700,000 is to supply HDMT with 35 systems over the next eight months starting in July of this year. 'We are extremely pleased to be working with HDMT to bring LuViva to Zhejiang Province and anticipate making initial shipments next month,' added Mark Faupel, Guided Therapeutics' CEO. 'Working directly with an exclusive provider of gynecology products that can potentially conduct two million LuViva tests each year is a major advance for GTI.' About Guided Therapeutics Guided Therapeutics, Inc. (OTCQB: GTHP) is the maker of a rapid and painless testing platform based on its patented biophotonic technology that utilizes light for the early detection of disease at the cellular level. The Company's first product is the LuViva® Advanced Cervical Scan, a non-invasive device used to detect cervical disease instantly and at the point of care. In a multi-center clinical trial with women at risk for cervical disease, the technology was able to detect cervical cancer up to two years earlier than conventional modalities, according to published reports. For more information, visit: The Guided Therapeutics LuViva ® Advanced Cervical Scan is an investigational device and is limited by federal law to investigational use in the U.S. LuViva, the wave logo and "Early detection, better outcomes" are registered trademarks owned by Guided Therapeutics, Inc. Forward-Looking Statements Disclaimer: A number of the matters and subject areas discussed in this news release that are not historical or current facts deal with potential future circumstances and developments. The discussion of such matters and subject areas is qualified by the inherent risks and uncertainties surrounding future expectations generally and also may materially differ from Guided Therapeutics' actual future experience involving any of or more of such matters and subject areas. Such risks and uncertainties include those related to the early stage of commercialization of products, the uncertainty of market acceptance of products, the uncertainty of development or effectiveness of distribution channels, the intense competition in the medical device industry, the sufficiency of capital raised in prior financings and the ability to realize their expected benefits, the uncertainty of future capital to develop products or continue as a going concern, the uncertainty of regulatory approval of products, and the dependence on licensed intellectual property, as well as those that are more fully described from time to time under the heading 'Risk Factors' in Guided Therapeutics' reports filed with the SEC, including Guided Therapeutics' Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and subsequent filings.
